APELLIS PHARMACEUTICALS INC (APLS) Forecast, Price Target & Analyst Ratings

NASDAQ:APLS • US03753U1060

Current stock price

40.89 USD
-0.05 (-0.12%)
At close:
40.91 USD
+0.02 (+0.05%)
Pre-Market:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for APELLIS PHARMACEUTICALS INC (APLS).

Forecast Snapshot

Consensus Price Target

Price Target
$37.23
-8.95% Downside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
Apr 30, 2026
Period
Q1 / 2026
EPS Estimate
-$0.36
Revenue Estimate
208.34M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
71.11%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$37.23
Upside
-8.95%
From current price of $40.89 to mean target of $37.23, Based on 27 analyst forecasts
Low
$18.18
Median
$41.82
High
$47.25

Price Target Revisions

1 Month
6.88%
3 Months
3.20%

Price Target Summary

27 Wall Street analysts provided a forecast for the next 12 months for APLS. The average price target is 37.23 USD. This implies a price decrease of -8.95% is expected in the next year compared to the current price of 40.89.
The average price target has been revised upward by 3.2% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

APLS Current Analyst RatingAPLS Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 5 10

Analyst Ratings History

APLS Historical Analyst RatingsAPLS Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 5 10 15 20 25

Analyst Ratings Consensus

ChartMill Buy Consensus
71.11%
APLS was analyzed by 27 analysts. The buy percentage consensus is at 71. So analysts seem to be have mildly positive about APLS.
In the last month the buy percentage fell by 8 points. So the trust of analysts is decreasing.
APLS was analyzed by 27 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-04-17Wells FargoDowngrade Overweight -> Equal-Weight
2026-04-02MizuhoMaintains Neutral -> Neutral
2026-04-01Cantor FitzgeraldDowngrade Overweight -> Neutral
2026-04-01BarclaysMaintains Equal-Weight -> Equal-Weight
2026-04-01Raymond JamesDowngrade Outperform -> Market Perform
2026-04-01JP MorganDowngrade Overweight -> Neutral
2026-04-01CitigroupDowngrade Buy -> Neutral
2026-04-01HC Wainwright & Co.Downgrade Buy -> Neutral
2026-03-31NeedhamDowngrade Buy -> Hold
2026-03-18Cantor FitzgeraldMaintains Overweight -> Overweight
2026-03-13Roth CapitalInitiate Sell -> Buy
2026-03-05MizuhoMaintains Neutral -> Neutral
2026-03-05JP MorganMaintains Overweight -> Overweight
2026-02-25RBC CapitalMaintains Sector Perform -> Sector Perform
2026-02-25WedbushMaintains Neutral -> Neutral
2026-02-25CitigroupMaintains Buy -> Buy
2026-02-25HC Wainwright & Co.Maintains Buy -> Buy
2026-01-28BarclaysInitiate Equal-Weight
2026-01-21B of A SecuritiesUpgrade Neutral -> Buy
2026-01-20Wells FargoMaintains Overweight -> Overweight
2026-01-13Cantor FitzgeraldMaintains Overweight -> Overweight
2026-01-13NeedhamMaintains Buy -> Buy
2025-12-19StifelMaintains Buy -> Buy
2025-11-06Wolfe ResearchInitiate Peer Perform
2025-11-05JP MorganMaintains Overweight -> Overweight

Next Earnings Forecast Details

Next Earnings Details

Release Date
Apr 30, 2026
Period
Q1 / 2026
EPS Estimate
-$0.36
Revenue Estimate
208.34M
Revenue Q2Q
24.91%
EPS Q2Q
51.63%
Number of Analysts
23

Next Earnings Revisions

Revenue (1 Month)
-0.11%
Revenue (3 Months)
5.92%
EPS (1 Month)
0.57%
EPS (3 Months)
23.72%

Next Earnings Summary

APLS is expected to report earnings on 4/30/2026. The consensus EPS estimate for the next earnings is -0.36 USD and the consensus revenue estimate is 208.34M USD.
The next earnings revenue estimate has been revised upward by 5.92% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
APLS revenue by date.APLS revenue by date.
396.591M
425.98%		781.367M
97.02%		1.004B
28.46%		882.48M
-12.08%		1.043B
18.19%		1.209B
15.92%		1.4B
15.80%		1.571B
12.21%		1.702B
8.34%		1.763B
3.58%		1.932B
9.59%
EBITDA
YoY % growth
APLS ebitda by date.APLS ebitda by date.
-515.337M
13.10%		-163.182M
68.33%		56.985M
134.92%		-90.486M
-258.79%		48.977M
154.13%		201.38M
311.17%		126.77M
-37.05%		238M
87.74%		344.93M
44.93%		448.61M
30.06%		1.011B
125.36%
EBIT
YoY % growth
APLS ebit by date.APLS ebit by date.
-517.121M
13.03%		-164.979M
68.10%		55.427M
133.60%		-128.702M
-332.20%		2.69M
102.09%		137.07M
4,995.54%		251.62M
83.57%		387.48M
53.99%		549.62M
41.84%		651.42M
18.52%		705.13M
8.25%
Operating Margin
APLS operating margin by date.APLS operating margin by date.
-130.39%-21.11%5.52%-14.58%0.26%11.34%17.97%24.66%32.29%36.95%36.50%
EPS
YoY % growth
APLS eps by date.APLS eps by date.
-4.48
26.92%		-1.45
67.63%		0.13
108.97%		-1.18
-1,007.45%		-0.26
78.19%		0.83
422.17%		1.67
100.97%		2.88
72.66%		3.57
24.11%		3.67
2.81%		4.38
19.45%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27
EPS
Q2Q % growth		-0.36
51.63%		-0.33
-1.32%		-0.28
-116.63%		-0.20
57.79%		-0.25
30.18%		-0.14
58.82%		-0.12
57.77%		-0.14
28.02%
Revenue
Q2Q % growth		208.34M
24.91%		212.97M
19.31%		223.23M
-51.32%		239.16M
19.63%		231.44M
11.09%		248.68M
16.77%		261.22M
17.02%		274.64M
14.84%
EBITDA
Q2Q % growth		-32.781M
60.45%		-26.451M
18.35%		-19.677M
-108.77%		-9.55M
80.74%		N/AN/AN/AN/A
EBIT
Q2Q % growth		-37.735M
54.72%		-34.752M
-4.40%		-26.939M
-112.07%		-17.353M
66.07%		N/AN/AN/AN/A

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

APLS Yearly Revenue VS EstimatesAPLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
APLS Yearly EPS VS EstimatesAPLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 -4 -6 -8

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
85.44%
EPS Next 5 Year
85.77%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
5.59%
Revenue Next 5 Year
8.87%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
44.48%
EBIT Next 5 Year
28.94%
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

APELLIS PHARMACEUTICALS INC / APLS Forecast FAQ

What do analysts expect the price target to be for APELLIS PHARMACEUTICALS INC (APLS)?

27 analysts have analysed APLS and the average price target is 37.23 USD. This implies a price decrease of -8.95% is expected in the next year compared to the current price of 40.89.

When does APELLIS PHARMACEUTICALS INC (APLS) report earnings?

APELLIS PHARMACEUTICALS INC (APLS) will report earnings on 2026-04-30.

What are the consensus estimates for APELLIS PHARMACEUTICALS INC (APLS) next earnings?

The consensus EPS estimate for the next earnings of APELLIS PHARMACEUTICALS INC (APLS) is -0.36 USD and the consensus revenue estimate is 208.34M USD.

Can you provide the analyst count for APELLIS PHARMACEUTICALS INC stock?

The number of analysts covering APELLIS PHARMACEUTICALS INC (APLS) is 27.